Recent studies have suggested an association between clinical responses and several promising biomarkers, including PD-1, PD-L1, CD3, tumor mutation burden (TMB), deficient DNA mismatch repair status (dMMR), and insertions and deletions (indels) (6). Here, PDCD1 is linked to neoplasm.